Table 2 BI 894999 effect on the proliferation of ex vivo-treated AML and MM primary patient samples
Indication | Patient | BI 894999 EC50 (nM) | Karyotype ISCN 2005 | Cytogenetic risk group classification |
|---|---|---|---|---|
AML | Patient 1 | 4 | 46,XX | Intermediate |
AML | Patient 2 | <1 | 46,XY | Intermediate |
AML | Patient 3 | 5 | 46,XY | Intermediate |
AML | Patient 4 | 1083 | 46,XY add(3)(q27),−7,del (10)(q22),+15 47,XY,−7,+8,+15 46,XY,der(15)t(1;15)(q10;p10) 46,XY | High |
AML | Patient 5 | 89 | 47,XY,−7,+8,+15 | High |
AML | Patient 6 | 2 | 46,XY,der(15)t(1;15)(q10;p10) | Intermediate |
AML | Patient 7 | 12 | 46,XY | Intermediate |
AML | Patient 8 | 2 | 45,XY,−7/45,XY, der (3)del (3) (p11p21),−7 | High |
AML | Patient 9 | 5 | 46,XY | Intermediate |
AML | Patient 10 | <1 | 46,XX,add(9)(q34),t(11;19)(q23;p13.3/ 46,XX | High |
AML | Patient 11 | 18 | 46,XY,t(9;11)(p11;q23) | High |
AML | Patient 12 | 4 | 46,XY | Intermediate |
AML | Patient 13 | <1 | 46,XX | Intermediate |
AML | Patient 14 | <1 | NA | NA |
AML | Patient 15 | 1 | 46,XY, inv(9)(p11q13) c | Intermediate |
AML | Patient 16 | <1 | NA | NA |
AML | Patient 17 | <1 | 46,XX,t(9;11)(p22;q23) | High |
AML | Patient 18 | <1 | 46,XX | Intermediate |
AML | Patient 19 | <1 | 46,XY | Intermediate |
AML | Patient 20 | <1 | 46,XY | Intermediate |
MM | Patient 1 | 52 | NA | NA |
MM | Patient 2 | 15 | NA | NA |
MM | Patient 3 | 7 | NA | NA |
MM | Patient 4 | >2000 | NA | NA |
MM | Patient 5 | 500 | NA | NA |
MM | Patient 6 | 421 | NA | NA |
MM | Patient 7 | 54 | NA | NA |
MM | Patient 8 | 3 | NA | NA |
MM | Patient 9 | 21 | NA | NA |
MM | Patient 10 | 1 | NA | NA |
MM | Patient 11 | 57 | NA | NA |
MM | Patient 12 | 1361 | NA | NA |
MM | Patient 13 | 2 | NA | NA |
MM | Patient 14 | 275 | NA | NA |
MM | Patient 15 | 352 | NA | NA |
